We are very proud at LEO Pharma that, as well as our firmly established therapy areas of Dermatology (skin) and Thrombosis (blood clots), we established a BioDermatology division in 2016 following the announcement of an exciting strategic partnership with Astra Zeneca. This marked the entry by LEO Pharma into developing innovative biologic therapies for skin conditions, firstly psoriasis and atopic dermatitis.
Building on our long-established heritage and expertise in topical treatments (those applied to the skin), starting from 2017, LEO Pharma is in the exciting position of providing products and resources for people living with psoriasis across the entire disease severity spectrum, in both primary and secondary care. This represents a key step in our growth journey.
Our BioDermatology division provides great opportunities for personal development for our current team to build on their skills and knowledge-base, as well as offering new roles for people who may want to join us on this exciting journey.
To learn more about opportunities in the team visit our Vacancies page
To learn more about our products visit Our Products page